Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
about
Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysisCanagliflozin Treatment in Patients with Type 2 Diabetes MellitusEfficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozinAdverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trialsPlace of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetesPatient profiling in diabetes and role of canagliflozin.SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.Short commentary on empagliflozin and its potential clinical impactEfficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled AnalysisSGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome.Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment optionsExtra-glycaemic properties of empagliflozin.The effect of SGLT2 inhibitors on cardiovascular events and renal function.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.A Review of the Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis.Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.Canagliflozin: A Review in Type 2 Diabetes.Sodium glucose co-transporter 2 inhibitors in patients with resistant hypertension: a case studySafety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study.Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus.
P2860
Q26773558-A79D6A64-7550-4481-A7BA-A98BAD22C0CAQ26777529-A4B5617D-BA2D-4102-8990-F423AA9D786CQ28250844-211A090C-485C-4BF5-92D1-022B39C619D9Q33567077-EC58946D-E56B-4028-BA79-8E38AF16C69CQ34699217-EEBA08EF-108C-44A4-88D9-5952A7EA9290Q34729268-596FFEFB-7F2C-4F5A-AA24-60CDD062D2EDQ35181821-365DE535-7D9B-45E4-AA57-D1BA1E27BD20Q35528797-18EAAEDB-AA8E-4931-8045-967FBF48A643Q36317577-9F7D8B3F-519C-4351-92B0-EB95FDB27CDFQ36762696-1AB67D24-8882-4FBF-9F4F-7B594D69A3B7Q36820604-6B3DDEB1-814E-47E6-9BD7-3A58759F8C7DQ37060855-E98FAF5C-5639-4302-BB87-2F3B3D1B2A4BQ37588842-4509DE7A-FAEB-4646-9A7A-6F5B560E3272Q37623972-675CADFB-1613-4BC5-A274-05F5019E529AQ38212007-788E070E-8DA4-48BA-87D6-9EB9CBF674EBQ38452883-83A07A7D-AADA-46F4-860F-228620F153DDQ38494441-1FC75388-5AF6-4D5C-856D-CC23EA5B8391Q38614488-66587454-087C-4DA8-8308-737521ED4013Q38619164-7B1E1854-A41A-43CB-B520-6A76DCF5D11CQ38715153-A1965759-4AE2-4CC8-8F7F-7341F26DB963Q38796262-D0A6B116-D060-4C40-AE37-FF43059186D1Q38827756-C1D2FDD9-BE70-4664-BBB9-8BE40F34781BQ39355218-EDF2DD33-90BF-4DC4-8804-CD39D28F58E5Q39540260-781A19FD-20C8-4717-9D91-6658A7573AD6Q40081685-40D4EAA3-848B-4C6B-B351-956D32DA4922Q41014893-4CF8A601-AA58-43F1-804D-E9BFDA67115BQ41143357-14325454-DFF7-4BD8-BCEC-D7556FA61256Q41605742-932CC693-DBA0-4A6A-ADB2-776FAA2CB525Q42688847-7FA7AB4C-4734-4BFB-BD26-E9A5A350DE05
P2860
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of canagli ...... d analysis of clinical studies
@ast
Efficacy and safety of canagli ...... d analysis of clinical studies
@en
type
label
Efficacy and safety of canagli ...... d analysis of clinical studies
@ast
Efficacy and safety of canagli ...... d analysis of clinical studies
@en
prefLabel
Efficacy and safety of canagli ...... d analysis of clinical studies
@ast
Efficacy and safety of canagli ...... d analysis of clinical studies
@en
P2093
P2860
P356
P1476
Efficacy and safety of canagli ...... d analysis of clinical studies
@en
P2093
Alan Sinclair
Albert Fung
Bruce Bode
Cristiana Mayer
Gary Meininger
Keith Usiskin
Mehul Desai
Stewart Harris
Ujjwala Vijapurkar
Wayne Shaw
P2860
P2888
P356
10.1186/1472-6823-14-37
P577
2014-04-18T00:00:00Z
P5875
P6179
1009448179